On May 5, SynAct Pharma held a Capital Markets Day in Stockholm featuring presentations from the management team, as well as Key Opinion Leaders in inflammation resolution and rheumatoid arthritis. The presentations highlighted the unmet medical need in rheumatoid arthritis and validated the potential of SynAct Pharma's drug candidate resomelagon in that area, but also in other diseases characterised by inflammation. BioStock contacted Torbjørn Bjerke to hear his highlights from the day.